Table 1.
Clinical progression of AML patients from the time of first diagnosis until relapse.
| Patient Code | Treatment at Diagnosis | Chemotherapy Cycles before CR | Time from CR1 to Relapse (Months) | Chemotherapy after Relapse | Response to Intensive Chemotherapy | Survival after Diagnosed First Relapse (Months) |
|---|---|---|---|---|---|---|
| PX1 | ICT/CCT | 2 | 8 | ICT | No CR2, death from chemoresistant disease | 3 |
| PX2 | ICT/CCT | 1 | 16 | ST | No CR2 | 1 |
| PX3 | ICT/CCT | 1 | 27 | ICT | Allogeneic retransplantation in CR2, death due to chemoresistant second relapse | 10 |
| PX4 | ICT/CCT | 1 | 13 | ST | No CR2 | 2 |
| PX5 | ICT/CCT | 1 | 5 | ICT | No CR2, death due to infection during neutropenia | 1 |
| PX6 | ICT/CCT | 1 | 3 | ICT | No CR2, death from chemoresistant disease | 2 |
| PX7 | ICT/CCT | 2 | 2 | ICT | No CR2 | 3 |
CR: 1, first remission; 2, second remission; ICT: induction chemotherapy; CCT: consolidation chemotherapy; ST: supportive therapy.